Effects of intramuscular meloxicam administration on prostaglandin E2 synthesis in the North American Bullfrog (Rana catesbeiana)

Larry J. Minter, Elsburgh O. Clarke, Jenessa Gjeltema, Kate E. Archibald, Lysa P. Posner, Gregory A. Lewbart

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Meloxicam is a commonly used nonsteroidal anti-inflammatory drug (NSAID) in veterinary medicine, but its use in amphibians has not been reported in the literature. NSAIDs are known to act by providing anti-inflammatory and analgesic actions by inhibiting the synthesis of prostaglandin E2 (PGE2). The objective of this study was to evaluate whether the intramuscular administration of meloxicam would decrease the circulating serum PGE2 levels in the North American bullfrog (Rana catesbeiana) following tissue trauma induced by a punch biopsy. Eighteen adult North American bullfrogs were randomly assigned to two treatment groups: meloxicam (0.1 mg/kg i.m.) and control (0.9% saline i.m.). Blood was obtained via cardiocentesis immediately prior to administration of the two treatment regimes and serum was frozen. A 4-mm punch biopsy was taken from the right triceps femoris muscle to induce an inflammatory response. Twenty-four hours later, a second blood sample was collected and serum was harvested and frozen. Serum PGE2 concentrations were measured using a commercial PGE2 enzyme assay (EIA) kit. Twenty-four hours following the biopsy, the mean circulating PGE2 levels of animals treated with meloxicam was 57.79 ± 12.35 pg/ml, which did not differ significantly from animals that were treated with saline (85.63 ± 17.55 pg/ml, P ≥ 0.05). The calculated means of the absolute change between the circulating baseline PGE2 levels and the postinjury circulating PGE2 levels were significantly lower in animals treated with meloxicam (13.11 ± 17.31 pg/ml) than in control animals treated with saline (46.14 ± 38.02 pg/ml) (P ≤ 0.05). These results suggest that the systemic administration of meloxicam at a dosage of 0.1 mg/kg once daily suppresses circulating serum PGE2 levels postinjury in the North American bullfrog.

Original languageEnglish (US)
Pages (from-to)680-685
Number of pages6
JournalJournal of Zoo and Wildlife Medicine
Volume42
Issue number4
DOIs
StatePublished - Dec 2011
Externally publishedYes

Fingerprint

meloxicam
Rana catesbeiana
Lithobates catesbeianus
Dinoprostone
prostaglandins
blood serum
synthesis
biopsy
Serum
nonsteroidal anti-inflammatory agents
Non-Steroidal Anti-Inflammatory Agents
Biopsy
animals
Veterinary Medicine
blood
Enzyme Assays
Amphibians
analgesics
intramuscular injection
veterinary medicine

Keywords

  • Meloxicam
  • nonsteroidal anti-inflammatory
  • North American bullfrog
  • prostaglandin e2
  • Rana catesbeiana

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

Effects of intramuscular meloxicam administration on prostaglandin E2 synthesis in the North American Bullfrog (Rana catesbeiana). / Minter, Larry J.; Clarke, Elsburgh O.; Gjeltema, Jenessa; Archibald, Kate E.; Posner, Lysa P.; Lewbart, Gregory A.

In: Journal of Zoo and Wildlife Medicine, Vol. 42, No. 4, 12.2011, p. 680-685.

Research output: Contribution to journalArticle

Minter, Larry J. ; Clarke, Elsburgh O. ; Gjeltema, Jenessa ; Archibald, Kate E. ; Posner, Lysa P. ; Lewbart, Gregory A. / Effects of intramuscular meloxicam administration on prostaglandin E2 synthesis in the North American Bullfrog (Rana catesbeiana). In: Journal of Zoo and Wildlife Medicine. 2011 ; Vol. 42, No. 4. pp. 680-685.
@article{adbcc25dd27b410b9696f1181f42fded,
title = "Effects of intramuscular meloxicam administration on prostaglandin E2 synthesis in the North American Bullfrog (Rana catesbeiana)",
abstract = "Meloxicam is a commonly used nonsteroidal anti-inflammatory drug (NSAID) in veterinary medicine, but its use in amphibians has not been reported in the literature. NSAIDs are known to act by providing anti-inflammatory and analgesic actions by inhibiting the synthesis of prostaglandin E2 (PGE2). The objective of this study was to evaluate whether the intramuscular administration of meloxicam would decrease the circulating serum PGE2 levels in the North American bullfrog (Rana catesbeiana) following tissue trauma induced by a punch biopsy. Eighteen adult North American bullfrogs were randomly assigned to two treatment groups: meloxicam (0.1 mg/kg i.m.) and control (0.9{\%} saline i.m.). Blood was obtained via cardiocentesis immediately prior to administration of the two treatment regimes and serum was frozen. A 4-mm punch biopsy was taken from the right triceps femoris muscle to induce an inflammatory response. Twenty-four hours later, a second blood sample was collected and serum was harvested and frozen. Serum PGE2 concentrations were measured using a commercial PGE2 enzyme assay (EIA) kit. Twenty-four hours following the biopsy, the mean circulating PGE2 levels of animals treated with meloxicam was 57.79 ± 12.35 pg/ml, which did not differ significantly from animals that were treated with saline (85.63 ± 17.55 pg/ml, P ≥ 0.05). The calculated means of the absolute change between the circulating baseline PGE2 levels and the postinjury circulating PGE2 levels were significantly lower in animals treated with meloxicam (13.11 ± 17.31 pg/ml) than in control animals treated with saline (46.14 ± 38.02 pg/ml) (P ≤ 0.05). These results suggest that the systemic administration of meloxicam at a dosage of 0.1 mg/kg once daily suppresses circulating serum PGE2 levels postinjury in the North American bullfrog.",
keywords = "Meloxicam, nonsteroidal anti-inflammatory, North American bullfrog, prostaglandin e2, Rana catesbeiana",
author = "Minter, {Larry J.} and Clarke, {Elsburgh O.} and Jenessa Gjeltema and Archibald, {Kate E.} and Posner, {Lysa P.} and Lewbart, {Gregory A.}",
year = "2011",
month = "12",
doi = "10.1638/2011-0126.1",
language = "English (US)",
volume = "42",
pages = "680--685",
journal = "Journal of Zoo and Wildlife Medicine",
issn = "1042-7260",
publisher = "American Association of Zoo Veterinarians",
number = "4",

}

TY - JOUR

T1 - Effects of intramuscular meloxicam administration on prostaglandin E2 synthesis in the North American Bullfrog (Rana catesbeiana)

AU - Minter, Larry J.

AU - Clarke, Elsburgh O.

AU - Gjeltema, Jenessa

AU - Archibald, Kate E.

AU - Posner, Lysa P.

AU - Lewbart, Gregory A.

PY - 2011/12

Y1 - 2011/12

N2 - Meloxicam is a commonly used nonsteroidal anti-inflammatory drug (NSAID) in veterinary medicine, but its use in amphibians has not been reported in the literature. NSAIDs are known to act by providing anti-inflammatory and analgesic actions by inhibiting the synthesis of prostaglandin E2 (PGE2). The objective of this study was to evaluate whether the intramuscular administration of meloxicam would decrease the circulating serum PGE2 levels in the North American bullfrog (Rana catesbeiana) following tissue trauma induced by a punch biopsy. Eighteen adult North American bullfrogs were randomly assigned to two treatment groups: meloxicam (0.1 mg/kg i.m.) and control (0.9% saline i.m.). Blood was obtained via cardiocentesis immediately prior to administration of the two treatment regimes and serum was frozen. A 4-mm punch biopsy was taken from the right triceps femoris muscle to induce an inflammatory response. Twenty-four hours later, a second blood sample was collected and serum was harvested and frozen. Serum PGE2 concentrations were measured using a commercial PGE2 enzyme assay (EIA) kit. Twenty-four hours following the biopsy, the mean circulating PGE2 levels of animals treated with meloxicam was 57.79 ± 12.35 pg/ml, which did not differ significantly from animals that were treated with saline (85.63 ± 17.55 pg/ml, P ≥ 0.05). The calculated means of the absolute change between the circulating baseline PGE2 levels and the postinjury circulating PGE2 levels were significantly lower in animals treated with meloxicam (13.11 ± 17.31 pg/ml) than in control animals treated with saline (46.14 ± 38.02 pg/ml) (P ≤ 0.05). These results suggest that the systemic administration of meloxicam at a dosage of 0.1 mg/kg once daily suppresses circulating serum PGE2 levels postinjury in the North American bullfrog.

AB - Meloxicam is a commonly used nonsteroidal anti-inflammatory drug (NSAID) in veterinary medicine, but its use in amphibians has not been reported in the literature. NSAIDs are known to act by providing anti-inflammatory and analgesic actions by inhibiting the synthesis of prostaglandin E2 (PGE2). The objective of this study was to evaluate whether the intramuscular administration of meloxicam would decrease the circulating serum PGE2 levels in the North American bullfrog (Rana catesbeiana) following tissue trauma induced by a punch biopsy. Eighteen adult North American bullfrogs were randomly assigned to two treatment groups: meloxicam (0.1 mg/kg i.m.) and control (0.9% saline i.m.). Blood was obtained via cardiocentesis immediately prior to administration of the two treatment regimes and serum was frozen. A 4-mm punch biopsy was taken from the right triceps femoris muscle to induce an inflammatory response. Twenty-four hours later, a second blood sample was collected and serum was harvested and frozen. Serum PGE2 concentrations were measured using a commercial PGE2 enzyme assay (EIA) kit. Twenty-four hours following the biopsy, the mean circulating PGE2 levels of animals treated with meloxicam was 57.79 ± 12.35 pg/ml, which did not differ significantly from animals that were treated with saline (85.63 ± 17.55 pg/ml, P ≥ 0.05). The calculated means of the absolute change between the circulating baseline PGE2 levels and the postinjury circulating PGE2 levels were significantly lower in animals treated with meloxicam (13.11 ± 17.31 pg/ml) than in control animals treated with saline (46.14 ± 38.02 pg/ml) (P ≤ 0.05). These results suggest that the systemic administration of meloxicam at a dosage of 0.1 mg/kg once daily suppresses circulating serum PGE2 levels postinjury in the North American bullfrog.

KW - Meloxicam

KW - nonsteroidal anti-inflammatory

KW - North American bullfrog

KW - prostaglandin e2

KW - Rana catesbeiana

UR - http://www.scopus.com/inward/record.url?scp=84255187173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255187173&partnerID=8YFLogxK

U2 - 10.1638/2011-0126.1

DO - 10.1638/2011-0126.1

M3 - Article

VL - 42

SP - 680

EP - 685

JO - Journal of Zoo and Wildlife Medicine

JF - Journal of Zoo and Wildlife Medicine

SN - 1042-7260

IS - 4

ER -